No connection

Search Results

INDV vs IRTC

INDV
Indivior Pharmaceuticals, Inc.
NEUTRAL
Price
$30.54
Market Cap
$3.82B
Sector
Healthcare
AI Confidence
85%
IRTC
iRhythm Holdings, Inc.
NEUTRAL
Price
$115.24
Market Cap
$3.72B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
INDV
18.62
IRTC
--
Forward P/E
INDV
8.87
IRTC
137.79
P/B Ratio
INDV
-38.95
IRTC
24.37
P/S Ratio
INDV
3.08
IRTC
4.98
EV/EBITDA
INDV
10.01
IRTC
-126.66

Profitability

Gross Margin
INDV
84.02%
IRTC
70.57%
Operating Margin
INDV
37.15%
IRTC
4.2%
Profit Margin
INDV
16.95%
IRTC
-5.96%
ROE
INDV
--
IRTC
-36.57%
ROA
INDV
19.22%
IRTC
-2.36%

Growth

Revenue Growth
INDV
19.7%
IRTC
27.1%
Earnings Growth
INDV
376.2%
IRTC
--

Financial Health

Debt/Equity
INDV
--
IRTC
4.79
Current Ratio
INDV
0.71
IRTC
4.63
Quick Ratio
INDV
0.49
IRTC
4.34

Dividends

Dividend Yield
INDV
--
IRTC
--
Payout Ratio
INDV
0.0%
IRTC
0.0%

AI Verdict

INDV NEUTRAL

INDV presents a stark contrast between operational excellence and financial fragility, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits explosive earnings growth (376% YoY) and trades significantly below its intrinsic value of $48.38, its balance sheet is highly distressed with a negative Price/Book ratio of -38.95 and a Current Ratio of 0.71. The forward P/E of 8.87 suggests an attractive valuation for growth, but the underlying solvency risks prevent a bullish rating. The investment thesis relies entirely on continued high-margin growth to offset structural financial weaknesses.

Strengths
Exceptional gross margins (84.02%) and operating margins (37.15%)
Explosive YoY earnings growth of 376.20%
Strong earnings track record with 3/4 recent quarters beating estimates
Risks
Severe financial health warning indicated by Piotroski F-Score of 2/9
Negative shareholders' equity as evidenced by Price/Book of -38.95
Liquidity risk with a Current Ratio (0.71) and Quick Ratio (0.49) well below 1.0
IRTC NEUTRAL

IRTC presents a stark contrast between fundamental health and growth potential, anchored by a weak Piotroski F-Score of 2/9. While the company demonstrates strong top-line revenue growth (27.1%) and impressive gross margins (70.57%), it is burdened by a high Debt/Equity ratio of 4.79 and a prohibitively expensive Forward P/E of 137.79. Recent earnings beats and a shift toward positive EPS provide a bullish catalyst, but these are offset by bearish insider activity and a complete lack of technical momentum. The stock is currently a speculative growth play rather than a value investment.

Strengths
Strong revenue growth of 27.10% YoY
High gross margins at 70.57%
Recent trend of beating earnings estimates (3/4 last quarters)
Risks
Critically low Piotroski F-Score (2/9) indicating poor financial health
Extreme valuation with a Forward P/E of 137.79 and Price/Book of 24.37
High leverage with a Debt/Equity ratio of 4.79

Compare Another Pair

INDV vs IRTC: Head-to-Head Comparison

This page compares Indivior Pharmaceuticals, Inc. (INDV) and iRhythm Holdings, Inc. (IRTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile